ClinicalTrials.

gov Search Results 09/02/2022

Title Status Study Results Conditions Interventions Locations
1 Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR Recruiting No Results Available •ER-Positive HER2-Negative Breast Cancer •Drug: AZD9833 •Research Site, Phoenix, Arizona, United States
+/HER2-MBC With Detectable ESR1m Before Progression
•Drug: AZD9833 Placebo •Research Site, Hot Springs National Park, Arkansas, United
(SERENA-6)
States
•Drug: Anastrozole
•Research Site, Little Rock, Arkansas, United States
•Drug: Anastrozole placebo
•Research Site, Long Beach, California, United States
•Drug: Letrozole
•Research Site, San Diego, California, United States
•Drug: Letrozole placebo
•Research Site, Santa Rosa, California, United States
•Drug: Palbociclib
•Research Site, Denver, Colorado, United States
•Drug: Abemaciclib
•Research Site, Grand Junction, Colorado, United States
•Drug: Luteinizing hormone-releasing
hormone (LHRH) agonist •Research Site, Lone Tree, Colorado, United States
•Research Site, Fort Myers, Florida, United States
•and 206 more
2 A Study Evaluating the Efficacy and Safety of Giredestrant Recruiting No Results Available •Estrogen Receptor (ER)-Positive, HER2- •Drug: Giredestrant •California Oncology of the Central Valley, Fresno, California,
Plus Everolimus Compared With Exemestane Plus Everolimus negative, Locally Advanced or Metastatic United States
•Drug: Exemestane
in Participants With Estrogen Receptor-Positive, HER2- Breast Cancer
•Emad Ibrahim, Md, Inc, Redlands, California, United States
Negative, Locally Advanced or Metastatic Breast Cancer •Drug: Everolimus
(evERA Breast Cancer) •Eastern CT Hematology and Oncology Associates, Norwich,
•Drug: LHRH Agonist
Connecticut, United States
•Drug: Dexamethasone Mouth Rinse
•Northwest Georgia Oncology Centers PC - Marietta, Marietta,
Georgia, United States
•Summit Cancer Care PC, Savannah, Georgia, United States
•Oncology Hematology West PC, Grand Island, Nebraska,
United States
•Nebraska Cancer Specialists; Oncology Hematology West, PC,
Omaha, Nebraska, United States
•San Juan Oncology Associates, Farmington, New Mexico,
United States
•Northwest Medical Specialties, PLLC; Research Department,
Tacoma, Washington, United States

- Page 1 of 28 -
 Title
3 A Study Evaluating the Efficacy and Safety of Giredestrant
Combined With Palbociclib Compared With Letrozole
Combined With Palbociclib in Participants With Estrogen
Receptor-Positive, HER2-Negative Locally Advanced or
Metastatic Breast Cancer (persevERA Breast Cancer)
4 A Phase 1/2 Trial of ARV-471 Alone and in Combination With
Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally
Advanced or Metastatic Breast Cancer
Status Study Results Conditions Interventions Locations
Recruiting No Results Available •Estrogen Receptor-Positive, HER2- •Drug: Giredestrant •Alaska Oncology and Hematology, Anchorage, Alaska, United
Negative Locally Advanced or Metastatic States
•Drug: Giredestrant-matched Placebo
Breast Cancer
•Long Beach Memorial Medical Center, Fountain Valley,
•Drug: Letrozole
California, United States
•Drug: Letrozole-matched Placebo
•Orange Coast Memorial Medical Center, Fountain Valley,
•Drug: Palbociclib California, United States
•Drug: LHRH Agonist •Los Angeles Hematology Oncology Medical Group, Los
Angeles, California, United States
•Kaiser Permanente - Oakland, Oakland, California, United
States
•California Cancer Associates for Research & Excellence, Inc.,
Poway, California, United States
•Kaiser Permanente - Roseville, Roseville, California, United
States
•Kaiser Permanente - San Francisco Medical Center, San
Francisco, California, United States
•Kaiser Permanente - San Leandro Medical Center, San
Leandro, California, United States
•Kaiser Permanente - South San Francisco, South San
Francisco, California, United States
•and 355 more
Recruiting No Results Available •Breast Cancer •Drug: ARV-471 •Clinical Trial Site, Palo Alto, California, United States
•Drug: ARV-471 in combination with •Clinical Trial Site, San Francisco, California, United States
palbociclib (IBRANCE®)
•Clinical Trial Site, Santa Monica, California, United States
•Clinical Trial Site, Norwalk, Connecticut, United States
•Clinical Trial Site, Fort Myers, Florida, United States
•Clinical Trial Site, Tampa, Florida, United States
•Clinical Trial Site, Chicago, Illinois, United States
•Clinical Trial Site, Boston, Massachusetts, United States
•Clinical Trial Site, Boston, Massachusetts, United States
•Clinical Trial Site, Ann Arbor, Michigan, United States
•and 7 more
- Page 2 of 28 -
 Title Status Study Results Conditions Interventions Locations
5 A Study Evaluating the Efficacy and Safety of Adjuvant Recruiting No Results Available •Early Breast Cancer •Drug: Giredestrant •Southern Cancer Center, Daphne, Alabama, United States
Giredestrant Compared With Physician's Choice of Adjuvant
•Drug: Endocrine Therapy of Physician's •CBCC Global Research Inc., at Comprehensive Blood and
Endocrine Monotherapy in Participants With Estrogen
Choice Cancer Center, Bakersfield, California, United States
Receptor-Positive, HER2-Negative Early Breast Cancer
(lidERA Breast Cancer) •Drug: LHRH Agonist •Arrowhead Regional Medical Center, Colton, California, United
States
•Cancer and Blood Specialty Clinic, Fountain Valley, California,
United States
•Long Beach Memorial Medical Center, Fountain Valley,
California, United States
•The Center for Cancer Prevention and Treatment at St.Joseph
Hospital of Orange, Orange, California, United States
•Kaiser Permanente - San Diego, San Diego, California, United
States
•Sansum Clinic, Santa Barbara, California, United States
•UCLA Hematology/Oncology, Santa Monica, California, United
States
•St Joseph Heritage Healthcare, Santa Rosa, California, United
States
•and 626 more
6 Endocrine Treatment Alone for Elderly Patients With Recruiting No Results Available •Breast Cancer •Behavioral: FACT-B •Washington University School of Medicine, Saint Louis,
Estrogen Receptor Positive Operable Breast Cancer and Low Missouri, United States
•Cancer of Breast •Drug: Goserelin
Recurrence Score
•Breast Neoplasms •Drug: Anastrozole
•Cancer of the Breast •Drug: Exemestane
•Drug: Fulvestrant
•Drug: Tamoxifen
•Other: Archived tissue collection
7 Study of H3B-6545 in Japanese Women With Estrogen Recruiting No Results Available •Breast Neoplasms •Drug: H3B-6545 •Eisai Trial Site 2, Chuo Ku, Japan
Receptor (ER)-Positive, Human Epidermal Growth Factor
•Drug: Antihistamine •Eisai Trial Site 1, Koto-Ku, Japan
Receptor 2 (HER2)-Negative Breast Cancer
8 Efficacy Evaluation of Enobosarm Monotherapy in Treatment Recruiting No Results Available •Metastatic Breast Cancer •Drug: Enobosarm •Alaska Oncology and Hematology, LLC., Anchorage, Alaska,
of AR+/ER+/HER2- Metastatic Breast Cancer United States
•Drug: Exemestane
•Ironwood Cancer and Research Centers, Chandler, Arizona,
United States
•Banner Health/ Banner MD Anderson Cancer Center, Gilbert,
Arizona, United States
•The Oncology Insitute of Hope and Innovation, Glendale,
California, United States
•Marin Cancer Care, Inc., Greenbrae, California, United States
•California Research Institute (CRI), Los Angeles, California,
United States
•University of California San Francisco Comprehensive Cancer
Center, San Francisco, California, United States
•Providence Medical Group, Santa Rosa, California, United
States
•Rocky Mountain Cancer Centers, Denver, Colorado, United
States
•GenesisCare USA, Aventura, Florida, United States
•and 49 more

- Page 3 of 28 -
 Title Status Study Results Conditions Interventions Locations
9 Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Recruiting No Results Available •Breast Cancer •Drug: Ipatasertib •Southern Highlands Cancer Centre, Bowral, New South Wales,
Estrogen Receptor Positive (ER+) Breast Cancer Following Australia
•Drug: Fulvestrant
Progression on First Line CDK 4/6 Inhibitor and Aromatase
•Lake Macquarie Private Hospital, Gateshead, New South
Inhibitor •Other: Placebo
Wales, Australia
•Gosford Hospital, Gosford, New South Wales, Australia
•Macquarie University Hospital, Macquarie University, New South
Wales, Australia
•Shoalhaven Cancer Care Centre, Nowra, New South Wales,
Australia
•Prince of Wales Hospital, Randwick, New South Wales,
Australia
•Sunshine Coast University Hospital, Birtinya, Queensland,
Australia
•Toowoomba Hospital, Toowoomba, Queensland, Australia
•Victorian Breast and Oncology Care, East Melbourne, Victoria,
Australia
•Frankston Hospital, Frankston, Victoria, Australia
•and 28 more
10 A Study of Imlunestrant, Investigator's Choice of Endocrine Recruiting No Results Available •Breast Neoplasms •Drug: Imlunestrant •Ironwood Cancer & Research Centers, Chandler, Arizona,
Therapy, and Imlunestrant Plus Abemaciclib in Participants United States
•Neoplasm Metastasis •Drug: Exemestane
With ER+, HER2- Advanced Breast Cancer
•Banner MD Anderson Cancer Center, Gilbert, Arizona, United
•Drug: Fulvestrant
States
•Drug: Abemaciclib
•Marin Cancer Care, Greenbrae, California, United States
•University of California, Davis - Health Systems, Sacramento,
California, United States
•Sharp Memorial Hospital, San Diego, California, United States
•Banner MD Anderson Cancer Center at North Colorado Medical
Center, Greeley, Colorado, United States
•Rocky Mountain Cancer Center, Lone Tree, Colorado, United
States
•Banner MD Anderson Cancer Center at McKee Medical Center,
Loveland, Colorado, United States
•Univ of Florida School of Medicine, Gainesville, Florida, United
States
•Florida Cancer Specialists, Saint Petersburg, Florida, United
States
•and 229 more
11 A Study of AC682 for the Treatment of Locally Advanced or Recruiting No Results Available •Breast Cancer •Drug: AC682 •Site 01, Denver, Colorado, United States
Metastatic ER+ Breast Cancer
•Site 02, Sarasota, Florida, United States
•Site 03, Nashville, Tennessee, United States
12 Pembrolizumab and Tamoxifen With or Without Vorinostat for Recruiting No Results Available •Anatomic Stage IV Breast Cancer AJCC v8 •Biological: Pembrolizumab •University of California, San Francisco, San Francisco,
the Treatment of Estrogen Receptor Positive Breast Cancer California, United States
•Prognostic Stage IV Breast Cancer AJCC •Drug: Tamoxifen
v8
•Drug: Vorinostat

- Page 4 of 28 -
 Title Status Study Results Conditions Interventions Locations
13 A Study to Evaluate the Efficacy and Safety of Giredestrant Recruiting No Results Available •Locally Advanced or Metastatic Breast •Drug: Phesgo •Los Angeles Hematology Oncology Medical Group, Los
in Combination With Phesgo (Pertuzumab, Trastuzumab, Cancer Angeles, California, United States
•Drug: Giredestrant
and Hyaluronidase-zzxf) Versus Phesgo in Participants With
•Maryland Oncology Hematology; Maryland Oncology
Locally Advanced or Metastatic Breast Cancer (heredERA •Drug: Docetaxel
Hematology, PA, Silver Spring, Maryland, United States
Breast Cancer)
•Drug: Paclitaxel
•Texas Oncology - Austin, Austin, Texas, United States
•Drug: LHRH Agonist
•Texas Oncology-Baylor Sammons Cancer Center, Dallas,
•Drug: Optional Endocrine Therapy of Texas, United States
Investigator's Choice
•Texas Oncology - El Paso, El Paso, Texas, United States
•Virginia Oncology Associates, Norfolk, Virginia, United States
•the First Affiliated Hospital of Bengbu Medical College, Bengbu
City, China
•Gesundheitszentrum Wetterau, Hochwaldkrankenhaus Bad
Nauheim; Gynäkologie/ onkolog. Tagesklinik, Bad Nauheim,
Germany
•Onkozentrum Dres. Göhler, Dresden, Germany
•HOPA MVZ GmbH, Hamburg, Germany
•and 43 more
14 A Study of LY3484356 in Women With Breast Cancer Before Recruiting No Results Available •Breast Cancer •Drug: LY3484356 •Winship Cancer Center Emory University, Atlanta, Georgia,
Having Surgery United States
•Northwestern Memorial Hosptial, Chicago, Illinois, United States
•Massachusetts General Hospital, Boston, Massachusetts,
United States
•Washington University School of Medicine, Saint Louis,
Missouri, United States
•Sarah Cannon Research Institute SCRI, Nashville, Tennessee,
United States
•Sarah Cannon Research Institute SCRI, Nashville, Tennessee,
United States
•Baylor College of Medicine, Houston, Texas, United States
•University of Texas MD Anderson Cancer Center, Houston,
Texas, United States
•University of Vermont Medical Center, Burlington, Vermont,
United States
•Institut Jules Bordet, Brussel - Capital, Belgium
•and 10 more
15 Palbociclib With Fulvestrant for Metastatic Breast Cancer After Recruiting No Results Available •Metastatic Breast Cancer •Drug: Palbociclib •Kimmel Cancer Center at Johns Hopkins at Sibley Memorial
Treatment With Palbociclib and an Aromatase Inhibitor Hospital, Washington, District of Columbia, United States
•Drug: Fulvestrant
•Anne Arundel Health System Research Institute, Inc.,
Annapolis, Maryland, United States
•Sidney Kimmel Comprehensive Cancer Center at Johns
Hopkins, Baltimore, Maryland, United States
•Allegheny Health Network (AHN) - Allegheny General Hospital
ONLY, Pittsburgh, Pennsylvania, United States
•Reading Hospital - McGlinn Cancer Institute, West Reading,
Pennsylvania, United States

- Page 5 of 28 -
 Title Status Study Results Conditions Interventions Locations
16 Phase I Clinical Trial of TQB3915 Tablets in Subjects With Recruiting No Results Available •Advanced Malignant Tumor •Drug: TQB3915 tablets •Sun Yat-Sen University Cancer Canter, Guangzhou,
Advanced Malignant Solid Tumors Guangdong, China
•Henan Cancer Hospital, Zhengzhou, Henan, China
•First Affiliated Hospital with Nanjin Medical University (Jiangsu
Province Hospital), Nanjing, Jiangsu, China
17 A Study of E7090 as Monotherapy and in Combination Recruiting No Results Available •Breast Neoplasms •Drug: E7090 •Eisai Trial Site 11, Nagoya, Aichi, Japan
With Other Anticancer Agents in Participants With Estrogen
•Drug: Fulvestrant •Eisai Trial Site 6, Kashiwa, Chiba, Japan
Receptor Positive (ER+) and Human Epidermal Growth
Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast •Drug: Exemestane •Eisai Trial Site 9, Matsuyama, Ehime, Japan
Cancer
•Eisai Trial Site 5, Yokohama, Kanagawa, Japan
•Eisai Trial Site 4, Sendai, Miyagi, Japan
•Eisai Trial Site 7, Chuo-ku, Osaka, Japan
•Eisai Trial Site 10, Kitaadachi-gun, Saitama, Japan
•Eisai Trial Site 3, Chuo-ku, Tokyo, Japan
•Eisai Trial Site 1, Koto-ku, Tokyo, Japan
•Eisai Trial Site 2, Shinagawa-ku, Tokyo, Japan
•Eisai Trial Site 8, Shinjuku-ku, Tokyo, Japan
18 Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Recruiting No Results Available •Breast Cancer •Drug: Avelumab •University of Alabama at Birmingham, Birmingham, Alabama,
Estrogen Receptor Positive Breast Cancer United States
•Drug: Endocrine therapy
•Sibley Memorial Hospital, Washington, District of Columbia,
•Drug: Palbociclib
United States
•Sidney Kimmel Comprehensive Cancer Center at Johns
Hopkins, Baltimore, Maryland, United States
•Allegheny Health Network, Pittsburgh, Pennsylvania, United
States
19 Palbociclib for HR Positive / HER2-negative Isolated Recruiting No Results Available •Breast Cancer Recurrent •Drug: Palbociclib 125mg •Medizinische Universität Graz (MUG), Graz, Austria
Locoregional Recurrence of Breast Cancer
•Drug: Standard endocrine therapy •Medizinische Universität Innsbruck - Univ.-Klinik f.
Frauenheilkunde, Innsbruck, Austria
•Uniklinikum Salzburg, Salzburg, Austria
•MUW - Universitätsklinik für Innere Medizin, Vienna, Austria
•Institut Sainte Catherine, Avignon, France
•Institut Bergonie, Bordeaux, France
•Polyclinique Bordeaux Nord, Bordeaux, France
•Centre Francois Baclesse, Caen, France
•Cêntre Hospitaler de Cholet, Cholet, France
•Centre Georges François Leclerc, Dijon, France
•and 42 more
20 Phase I Study to Evaluate SCR-6852 Alone or in Combination Recruiting No Results Available •Breast Cancer •Drug: SCR-6852 •Fudan University Shanghai Cancer Center, Shanghai,
in ER+, HER2- Locally Advanced or Metastatic Breast Cancer Shanghai, China
•Drug: Palbociclib

- Page 6 of 28 -
 Title Status Study Results Conditions Interventions Locations
21 A Comparative Study of AZD9833 Plus Palbociclib Versus Recruiting No Results Available •ER-Positive HER2-Negative Breast Cancer •Drug: AZD9833 •Research Site, Mobile, Alabama, United States
Anastrozole Plus Palbociclib in Patients With ER-Positive
•Drug: Anastrozole •Research Site, Springdale, Arkansas, United States
HER2 Negative Breast Cancer Who Have Not Received Any
Systemic Treatment for Advanced Disease. •Drug: Anastrozole placebo •Research Site, Harbor City, California, United States
•Drug: AZD9833 placebo •Research Site, Lone Tree, Colorado, United States
•Drug: Palbociclib •Research Site, Fort Myers, Florida, United States
•Drug: Luteinizing hormone-releasing •Research Site, Jacksonville, Florida, United States
hormone (LHRH) agonist
•Research Site, West Palm Beach, Florida, United States
•Research Site, Evergreen Park, Illinois, United States
•Research Site, Urbana, Illinois, United States
•Research Site, Fort Wayne, Indiana, United States
•and 286 more
22 A Study to Investigate the Biological Effects of AZD9833 in Recruiting No Results Available •HER2-negative Breast Cancer •Drug: AZD9833 •Research Site, Batumi, Georgia
Women With ER-positive, HER2 Negative Primary Breast
•Research Site, Tbilisi, Georgia
Cancer
•Research Site, Tbilisi, Georgia
•Research Site, Tbilisi, Georgia
•Research Site, Tbilisi, Georgia
•Research Site, Tbilisi, Georgia
•Research Site, Aguascalientes, Mexico
•Research Site, D.F, Mexico
•Research Site, Mexico City, Mexico
•Research Site, México, Mexico
•and 9 more
23 Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Recruiting No Results Available •Ductal Breast Carcinoma In Situ •Drug: Afimoxifene •Northwestern University, Chicago, Illinois, United States
Delivered Through the Breast Skin to Control Ductal
•Estrogen Receptor Positive •Other: Laboratory Biomarker Analysis •Saint Elizabeth Medical Center South, Edgewood, Kentucky,
Carcinoma in Situ (DCIS) of the Breast
United States
•Other: Placebo
•Mayo Clinic, Rochester, Minnesota, United States
•Drug: Tamoxifen Citrate
•Memorial Sloan-Kettering Cancer Center, New York, New York,
United States
•Duke University Medical Center, Durham, North Carolina, United
States
•Cleveland Clinic, Cleveland, Ohio, United States
24 AZD9833 China PK Study Recruiting No Results Available •ER+, HER2-, Metastatic Breast Cancer •Drug: AZD9833 •Research Site, Beijing, China
•Drug: AZD9833 with palbociclib •Research Site, Chengdu, China
•Drug: AZD9833 with everolimus •Research Site, Nanjing, China
•Research Site, Shanghai, China
•Research Site, Wuhan, China
•Research Site, Zhengzhou, China

- Page 7 of 28 -
 Title Status Study Results Conditions Interventions Locations
25 Study With Atezolizumab in Combination With Trastuzumab Recruiting No Results Available •Breast Cancer •Drug: Atezolizumab + Trastuzumab + •H. Clínico San Cecilio de Granada, Granada, Andalucía, Spain
and Vinorelbine in HER2-positive Advanced/Metastatic Breast Vinorelbine
•Institut Català d'Oncologia Hospitalet, Hospitalet de Llobregat,
Cancer
Barcelona, Spain
•Hospital Universitario de Canarias, Tenerife, Islas Canarias,
Spain
•Complejo Hospitalario Universitario A Coruña (CHUAC), A
Coruña, La Coruña, Spain
•Hospital General Universitario de Alicante, Alicante, Spain
•Hospital del Mar, Barcelona, Spain
•Hospital Clinic de Barcelona, Barcelona, Spain
•Hospital Universitari Vall d' Hebron, Barcelona, Spain
•Hospital San Pedro de Alcántara, Cáceres, Spain
•Hospital de León, León, Spain
•and 5 more
26 A Study in Patients With Advanced Breast Cancer Recruiting No Results Available •HER2-negative Breast Cancer •Drug: Part 1 •Cedars-Sinai Medical Centre, Los Angeles, California, United
States
•Advanced Breast Cancer •Drug: Part 2
•Hoag Memorial Hospital Presbyterian, Newport Beach,
•Hormone Receptor-positive Breast Cancer •Drug: Part 3
California, United States
•Georgia cancer centre, Augusta, Georgia, United States
•The University of Chicago, Chicago, Illinois, United States
•Michigan Center of Medical Research, Farmington Hills,
Michigan, United States
•Narayana Multispeciality Hospital, Ahmedabad, Gujarat, India
•HealthCare Global Enterprises Ltd, Bangalore, Karnataka, India
•Amrita Institute of Medical Sciences (AIMS), Kochi, Kerala, India
•Prince Aly Khan Hospital, Mumbai, Maharashtra, India
•HCG Manavata cancer Centre, Nashik, Maharashtra, India
•and 3 more
27 Abemaciclib With Letrozole in Recurrent or Persistent Recruiting No Results Available •Endometrial Cancer •Drug: Letrozole •Massachusetts General Hospital Cancer Center, Boston,
Endometrial Cancer Massachusetts, United States
•Drug: Abemaciclib
•Beth Israel Deaconess Medical Center (BIDMC), Boston,
Massachusetts, United States
•Dana Farber Cancer Institute, Boston, Massachusetts, United
States

- Page 8 of 28 -
 Title Status Study Results Conditions Interventions Locations
28 Neoadjuvant and Adjuvant Ribociclib and ET for Clinically Recruiting No Results Available •Breast Cancer Stage II •Drug: Ribociclib (neoadjuvant) •Sainte Catherine - Institut du Cancer Avignon Provence,
High-risk ER+ and HER2- Breast Cancer Avignon, France
•Drug: Chemotherapy (adjuvant)
•Centre Hospitalier Universitaire de Besancon, Besançon,
•Drug: Ribociclib (adjuvant)
France
•Hôpital Simone veil de Blois, Blois, France
•Centre François Baclesse, Caen, France
•Centre Hospitalier de Cholet, Cholet, France
•Centre Jean Perrin, Clermont-Ferrand, France
•Centre Hospitalier Universitaire de Grenoble Alpes, Grenoble,
France
•Centre Hospitalier Départemental de Vendee, La Roche-sur-
Yon, France
•Hôpital Franco Britanique Fondation Cognacq Jay, Levallois-
Perret, France
•Centre Oscar lambret, Lille, France
•and 40 more
29 DNA-Guided Second Line Adjuvant Therapy For High Recruiting No Results Available •Breast Cancer •Drug: Palbociclib •University of Arizona Cancer Center, Tucson, Arizona, United
Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 States
•Drug: Fulvestrant
Negative Breast Cancer
•USC/Norris Comprehensive Cancer Center, Los Angeles,
•Drug: Adjuvant Therapy
California, United States
•Cedars-Sinai Medical Center, Los Angeles, California, United
States
•University of Colorado Cancer Center, Aurora, Colorado, United
States
•Yale Cancer Center, New Haven, Connecticut, United States
•Winship Cancer Institute of Emory University, Atlanta, Georgia,
United States
•Louisiana State University Health Sciences Center- New
Orleans, New Orleans, Louisiana, United States
•New Mexico Cancer Care Alliance, Albuquerque, New Mexico,
United States
•Icahn School of Medicine at Mount Sinai, New York, New York,
United States
•Stony Brook University Cancer Center, Stony Brook, New York,
United States
•and 5 more
30 Elacestrant in Preoperative Setting, a Window of Opportunity Recruiting No Results Available •Breast Cancer •Drug: Elacestrant •ICO Badalona, Badalona, Barcelona, Spain
Study
•Hormone Receptor Positive Breast •Hospital General de Catalunya, Sant Cugat Del Vallès,
Carcinoma Barcelona, Spain
•Hospital Universitari Vall d'Hebron, Barcelona, Spain
•Hospital Clinic Barcelona, Barcelona, Spain
31 Study of TTI-101 in Combination for Participants With Recruiting No Results Available •Breast Cancer •Drug: TTI-101 •Gabrail Cancer Center Research, Canton, Ohio, United States
Metastatic Hormone Receptor-Positive and Human Epithelial
•Drug: Palbociclib •University of Texas MD Anderson Cancer Center, Houston,
Receptor 2 (HER2)-Negative Breast Cancer
Texas, United States
•Drug: Aromatase inhibitor (AI)

- Page 9 of 28 -
 Title Status Study Results Conditions Interventions Locations
32 Efficacy & Safety Evaluation of Enobosarm in Combo With Recruiting No Results Available •Metastatic Breast Cancer •Drug: Enobosarm & Abemaciclib Combo •Ironwood Cancer & Research Centers, Chandler, Arizona,
Abemaciclib in Treatment of ER+HER2- Metastatic Breast United States
•Drug: non-steroidal AI, or steroidal AI
Cancer
(exemestane with or without everolimus) or •Banner MDACC, Gilbert, Arizona, United States
Fulvestrant
•Arizona Oncology Associates, PC-HOPE, Tucson, Arizona,
United States
•Los Angeles Cancer Network One Oncology, Los Angeles,
California, United States
•The Oncology Institute of Hope & Innovation, Lynwood,
California, United States
•Sharp Center for Research, San Diego, California, United States
•Med OncologyHematology Consultants, PA Newark, Newark,
Delaware, United States
•Lakes Research, Miami Lakes, Florida, United States
•Maryland Oncology Hematology, P.A., Annapolis, Maryland,
United States
•University of Mississippi Medical Center, Jackson, Mississippi,
United States
•and 15 more
33 TQB3616 Capsules Plus Fulvestrant Compared to Placebo Recruiting No Results Available •HR-positive,HER2-negative in Advanced •Drug: TQB3616 capsules •The Fifth Medical Center of PLA General Hospital, Beijing,
Plus Fulvestrant in Previously Treated Breast Cancer in Breast Cancer Beijing, China
•Drug: TQB3616-matching placebo
Clinical Trail
•Beijing Cancer Hosptital, Beijing, Beijing, China
•Drug: Fluvestrin injection
34 A Study of LXI-15029 in Patients With Advanced Malignant Recruiting No Results Available •Advanced Breast Cancer •Drug: LXI-15029 •Cancer Hospital Chinese Academy of Medical Sciences, Beijing,
Solid Tumors China
•Drug: LXI-15029+Exemestane
35 A Dose Escalation/Expansion Study of Oral OP-1250 in Recruiting No Results Available •Hormone Receptor Positive Breast •Drug: OP-1250 •Advent Health, Orlando, Florida, United States
Subjects With Advanced and/or Metastatic HR+, HER2- Carcinoma
•Florida Cancer Center, Sarasota, Florida, United States
Breast Cancer
•HER2-negative Breast Cancer
•OHSU Knight Cancer Institute, Portland, Oregon, United States
•Sarah Cannon Research Institute, Nashville, Tennessee, United
States
•Macquarie University, Sydney, New South Wales, Australia
•Westmead, Westmead, New South Wales, Australia
•ICON Cancer Centre, Auchenflower, Queensland, Australia
•Cancer Research South Australia, Adelaide, South Australia,
Australia
•Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
36 A Phase 1 Study of Oral OP-1250 in Combination With Recruiting No Results Available •Breast Cancer •Drug: OP-1250 •Site 6104, Westmead, New South Wales, Australia
Palbociclib in HR+/HER2- Breast Cancer Patients
•Drug: Palbociclib •Site 6102, South Brisbane, Queensland, Australia
•Site 6101, Clayton, Victoria, Australia
•Site 6103, Geelong, Victoria, Australia
•Site 6105, Nedlands, Western Australia, Australia

- Page 10 of 28 -
 Title Status Study Results Conditions Interventions Locations
37 A Study Evaluating the Efficacy and Safety of Multiple Recruiting No Results Available •Inoperable, Locally Advanced or •Drug: Giredestrant •City of Hope, Duarte, California, United States
Treatment Combinations in Participants With Breast Cancer Metastatic, ER-positive Breast Cancer
•Drug: Abemaciclib •University of California, San Francisco (UCSF), San Francisco,
California, United States
•Drug: Ipatasertib
•Los Angeles Biomedical Research Institute at Harbor-UCLA
•Drug: Inavolisib
Medical Center, Santa Monica, California, United States
•Drug: Ribociclib
•Stanford Cancer Institute (SCI), Stanford, California, United
•Drug: Everolimus States
•Drug: Samuraciclib •Massachusetts General Hospital, Boston, Massachusetts,
United States
•Drug: PH FDC SC
•Regional Cancer Care Associates LLC (RCCA) - Freehold
•Drug: Palbociclib Location, Freehold, New Jersey, United States
•Drug: Atezolizumab •Regional Cancer Care Associates LLC - Howell Division,
Howell, New Jersey, United States
•Levine Cancer Institute, Charlotte, North Carolina, United States
•Thomas Jefferson University Hospital;Medical Oncology,
Philadelphia, Pennsylvania, United States
•University of Pittsburgh Cancer Institute, Pittsburgh,
Pennsylvania, United States
•and 18 more
38 Locoregional Treatment and Palbociclib in de Novo, Recruiting No Results Available •Breast Cancer Stage IV •Drug: Palbociclib •Institut de Cancérologie de l'Ouest-Site Paul Papin, Angers,
Treatment Naive, Stage IV ER+, HER2- Breast Cancer France
•Radiotherapy •Other: locoregional treatment
Patients
•Institut Sainte Catherine, Avignon, France
•Surgery
•Centre François Baclesse, Caen, France
•Hôpital privé sainte Marie, Chalon-sur-Saône, France
•CH Cholet, Cholet, France
•Centre Jean Perrin, Clermont-Ferrand, France
•Centre George François Leclerc, Dijon, France
•Centre Léon Bérard, Lyon, France
•Hôpital St Joseph, Marseille, France
•Institut Paoli Calmettes, Marseille, France
•and 16 more
39 First-in-Human Study of RGT-419B Alone and With Endocrine Recruiting No Results Available •Breast Cancer •Drug: RGT-419B •Hem-Onc Associates of the Treasure Coast, Port Saint Lucie,
Therapy in Subjects With HR-Positive, HER2-Negative Florida, United States
•Drug: RGT-419B in combination with
Advanced/Metastatic Breast Cancer
hormonal therapy
40 Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Recruiting No Results Available •Triple Negative Breast Cancer •Drug: Nab-paclitaxel + Carboplatin •The Fourth Hospital of Hebei Medical University, Shijiazhuang,
Capecitabine in the Treatment of Advanced Triple-negative Hebei, China
•Nab-paclitaxel •Drug: Nab-paclitaxel + Capecitabine
Breast Cancer

- Page 11 of 28 -
 Title Status Study Results Conditions Interventions Locations
41 De-escalation Adjuvant Chemo in HER2+/ER-/Node-neg Early Recruiting No Results Available •HER2-positive Breast Cancer •Drug: Pertuzumab and tratuzumab fixed •GZA Ziekenhuisen Campus Sint-Augustinus - Iridium
BC Patients Who Achieved pCR After Neoadjuvant Chemo & dose combination Kankernetwerk, Antwerp, Wilrijk, Belgium
•ER-Negative Breast Cancer
Dual HER2 Blockade
•Drug: Trastuzumab emtansine •OLV ziekenhuis, Aalst, Belgium
•PR-Negative Breast Cancer
•Ziekenhuisnetwerk Jan Palfijn, Antwerp, Belgium
•Node-negative Breast Cancer
•Cliniques Universtaires Saint-Luc, Brussels, Belgium
•Grand Hôpital de Charleroi, Charleroi, Belgium
•Heilig Hartziekenhuis, Lier, Belgium
•CHU UCL Namur Sainte-Elisabeth, Namur, Belgium
•Institut de Cancérologie de l'Ouest - Angers, Angers, France
•Institut Sainte Catherine, Avignon, France
•CHRU Jean Minjoz, Besançon, France
•and 22 more
42 Study to Assess the Safety and Tolerability of PF-07220060 Recruiting No Results Available •Breast Cancer •Drug: PF-07220060 + PF-07104091 •Massachusetts General Hospital, Boston, Massachusetts,
in Combination With PF-07104091 in Participants With Breast combination dose escalation United States
•Solid Tumors
Cancers or Solid Tumors and to Assess the Safety and
•Drug: PF-07104091 + PF-07220060 + •START Midwest, Grand Rapids, Michigan, United States
Tolerability of PF-07220060 and PF-07104091 in Combination
fulvestrant dose expansion
With Endocrine Therapy in Participants With Breast Cancer. •The University of Texas MD Anderson Cancer Center, Houston,
•Drug: PF-07104091 + PF-07220060 + Texas, United States
letrozole dose expansion
43 Phase I Study of the HS-10352 in Patients With Advanced Recruiting No Results Available •Breast Cancer •Drug: HS-10352 •SUN YAT-SEN Memorial Hospital, Guanzhou, Guangdong,
Breast Cancer China
•Hunan Cancer Hospital, Changsha, Hunan, China
•Fudan University Shanghai Cancer Center, Shanghai,
Shanghai, China
44 A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Recruiting No Results Available •Advanced Solid Tumor •Drug: SY-5609 •Cedars-Sinai Medical Center, Los Angeles, California, United
Solid Tumors States
•Breast Cancer •Drug: Fulvestrant
•Orlando Health Cancer Institute, Orlando, Florida, United States
•Small-cell Lung Cancer •Drug: Gemcitabine
•Emory University, Atlanta, Georgia, United States
•Pancreatic Cancer •Drug: Nab-paclitaxel
•Johns Hopkins University, Baltimore, Maryland, United States
•Massachusetts General Hospital, Boston, Massachusetts,
United States
•Dana Farber Cancer Institute, Boston, Massachusetts, United
States
•University of Michigan, Ann Arbor, Michigan, United States
•START Midwest, LLC, Grand Rapids, Michigan, United States
•Duke University, Durham, North Carolina, United States
•Stephenson Cancer Center, Oklahoma City, Oklahoma, United
States
•and 4 more

- Page 12 of 28 -
 Title Status Study Results Conditions
45 Crizotinib in Lobular Breast, Diffuse Gastric and Triple Recruiting No Results Available •Lobular Breast Carcinoma
Negative Lobular Breast Cancer or CDH1-mutated Solid
•Gastric Cancer
Tumours
•Triple Negative Breast Cancer
•CDH1 Gene Mutation
46 A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Recruiting No Results Available •Triple-negative Breast Cancer
Participants With Solid Tumors (MK-2140-002)
•Non-squamous Non-small-cell Lung
Cancer
•NSCLC
•Estrogen-receptor-positive Breast Cancer
•Progesterone-receptor-positive Breast
Cancer
•Estrogen-receptor-negative Breast Cancer
•ER-negative Breast Cancer
•Progesterone-receptor Negative Breast
Cancer
•PR-negative Breast Cancer
•HER2-negative Breast Cancer
•and 5 more
47 Radiation Therapy, Palbociclib, and Hormone Therapy in Recruiting No Results Available •Anatomic Stage IV Breast Cancer AJCC v8
Treating Breast Cancer Patients With Bone Metastasis
•Estrogen Receptor Positive
•HER2/Neu Negative
•Metastatic Breast Carcinoma
•Metastatic Malignant Neoplasm in the Bone
•Progesterone Receptor Positive
•Prognostic Stage IV Breast Cancer AJCC
v8
Interventions Locations
•Drug: Crizotinib Oral Capsule [Xalkori] •Beatson West of Scotland Cancer Centre, Glasgow, United
Kingdom
•Drug: Fulvestrant 50 MG/ML Prefilled
Syringe [Faslodex or generic] •St Luke's Cancer Centre, Guildford, United Kingdom
•Clatterbridge Cancer Centre, Liverpool, United Kingdom
•Royal Marsden NHS Foundation Trust, London, United Kingdom
•Guys and St Thomas NHS Foundation Trust, London, United
Kingdom
•University College London Hospital, London, United Kingdom
•The Christie NHS Foundation Trust, Manchester, United
Kingdom
•Weston Park Cancer Centre, Sheffield, United Kingdom
•Drug: Zilovertamab vedotin •Memorial Regional Hospital-Memorial Cancer Institute ( Site
0005), Hollywood, Florida, United States
•AdventHealth Orlando ( Site 0003), Orlando, Florida, United
States
•John Theurer Cancer Center at Hackensack University Med Ctr
( Site 0002), Hackensack, New Jersey, United States
•Memorial Sloan Kettering Cancer Center ( Site 0007), New
York, New York, United States
•MD Anderson ( Site 0001), Houston, Texas, United States
•The University of Texas Health Science Center at San Antonio
( Site 0004), San Antonio, Texas, United States
•Swedish Medical Center ( Site 0008), Seattle, Washington,
United States
•Cross Cancer Institute ( Site 0012), Edmonton, Alberta, Canada
•BC Cancer Vancouver ( Site 0011), Vancouver, British
Columbia, Canada
•Princess Margaret Cancer Centre ( Site 0006), Toronto, Ontario,
Canada
•Jewish General Hospital ( Site 0013), Montreal, Quebec,
Canada
•Drug: Anastrozole •Grady Health System, Atlanta, Georgia, United States
•Drug: Exemestane •Emory University Hospital Midtown, Atlanta, Georgia, United
States
•Drug: Fulvestrant
•Piedmont Hospital, Atlanta, Georgia, United States
•Drug: Letrozole
•Emory University Hospital/Winship Cancer Institute, Atlanta,
•Drug: Palbociclib
Georgia, United States
•Radiation: Radiation Therapy
•Emory Saint Joseph's Hospital, Atlanta, Georgia, United States
•Drug: Tamoxifen
•Northside Hospital, Atlanta, Georgia, United States
•Augusta University Medical Center, Augusta, Georgia, United
States
•John B. Amos Cancer Center, Columbus, Georgia, United
States
•Lewis Cancer and Research Pavilion at Saint Joseph's/Candler,
Savannah, Georgia, United States
•Maine Medical Center-Bramhall Campus, Portland, Maine,
United States

- Page 13 of 28 -
 Title Status Study Results Conditions Interventions Locations
48 T-VEC With Chemotherapy or Endocrine Therapy in Treating Recruiting No Results Available •Anatomic Stage III Breast Cancer AJCC v8 •Drug: Anastrozole •University of California, San Francisco, San Francisco,
Participants With HER2- Negative Breast Cancer California, United States
•Anatomic Stage IIIA Breast Cancer AJCC •Drug: Exemestane
v8
•Drug: Fulvestrant
•Anatomic Stage IIIB Breast Cancer AJCC
•Drug: Letrozole
v8
•Drug: Paclitaxel
•Anatomic Stage IIIC Breast Cancer AJCC
v8 •Biological: Talimogene Laherparepvec
•Anatomic Stage IV Breast Cancer AJCC v8 •Drug: Tamoxifen
•Estrogen Receptor Positive •Drug: Nab paclitaxel
•HER2/Neu Negative •Drug: Gemcitabine
•Invasive Breast Carcinoma •Drug: Carboplatin
•Prognostic Stage III Breast Cancer AJCC
v8
•Prognostic Stage IIIA Breast Cancer AJCC
v8
•and 4 more
49 Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Recruiting No Results Available •Breast Cancer •Drug: Letrozole •Fudan University Shanghai Cancer Center, Shanghai, China
Subjects With Dual-receptor Positive(ER+/HER2+) Advanced
•Drug: Pyrotinib
Breast Cancer
•Drug: Dalpiciclib(SHR6390)
•Drug: Fulvestrant
50 Pre-op Pembro + Radiation Therapy in Breast Cancer (P- Recruiting No Results Available •Triple Negative Breast Cancer •Radiation: Radiation Therapy Boost •Sibley Memorial Hospital, Washington, District of Columbia,
RAD) United States
•Hormone Receptor Positive (HR+), HER2- •Drug: Pembrolizumab
negative Breast Cancer •Johns Hopkins, Baltimore, Maryland, United States
•Drug: Paclitaxel
•Biopsy-proven, Positive Lymph Node(s) •Massachusetts General Hospital, Boston, Massachusetts,
•Drug: Carboplatin
United States
•Drug: Cyclophosphamide
•Dana Farber Cancer Institute, Boston, Massachusetts, United
•Drug: Doxorubicin States
•Drug: Capecitabine •Mayo Clinic - Rochester, Rochester, Minnesota, United States
•Montefiore Medical Center, Bronx, New York, United States
•Memorial Sloan Kettering Cancer Center, New York, New York,
United States
•University of North Carolina Medical Center, Chapel Hill, North
Carolina, United States
•Duke University Medical Center, Durham, North Carolina, United
States
51 MAintenance Therapy With Aromatase Inhibitor in Epithelial Recruiting No Results Available •Ovarian Neoplasm Epithelial •Drug: Letrozole 2.5mg •Krankenhaus der Barmherzigen Brüder Graz, Graz, Austria
Ovarian Cancer (MATAO)
•Fallopian Tube Neoplasms •Other: Placebo •Medizinische Universität Graz, Graz, Austria
•Peritoneal Neoplasms •Medizinische Universität Innsbruck, Innsbruck, Austria
•High-grade Serous Ovarian Carcinoma •Landeskrankenhaus Hochsteiermark Leoben, Leoben, Austria
(HGSOC)
•Ordensklinikum Linz Barmherzige Schwestern, Linz, Austria
•Low-grade Serous Ovarian Carcinoma
•Universitätsklinikum Salzburg, Salzburg, Austria
(LGSOC)
•Medizinische Universität Wien, Wien, Austria
•Ovarian Endometrioid Carcinoma
•Klinik Hietzing Wien, Wien, Austria
•Universitätsspital Basel, Basel, Basel Stadt, Switzerland
•Kantonsspital Aarau AG, Aarau, Kanton Aargau, Switzerland
•and 19 more

- Page 14 of 28 -
 Title Status Study Results Conditions Interventions Locations
52 The Effects of Short-term Preoperative Treatment With Recruiting No Results Available •Breast Cancer •Drug: Tamoxifen Citrate •Johns Hopkins Bayview Hospital, Baltimore, Maryland, United
Hormonal Therapy on Gene Profiles in Breast Cancer States
•Drug: Letrozole
•Drug: Exemestane
•Diagnostic Test: Blueprint
•Diagnostic Test: Mammaprint
53 A Study of XmAb®23104 in Subjects With Selected Advanced Recruiting No Results Available •Melanoma (Excluding Uveal Melanoma) •Biological: XmAb®23104 •UC San Diego Moores Cancer Center, San Diego, California,
Solid Tumors (DUET-3) United States
•Cervical Carcinoma •Biological: Yervoy® (ipilimumab)
•University of Colorado Hospital - Anschutz Cancer Pavilion,
•Pancreatic Carcinoma
Aurora, Colorado, United States
•Breast Carcinoma That is Estrogen
•Sarah Cannon Research Institute at HealthONE, Denver,
Receptor, Progesterone Receptor, and
Colorado, United States
Her2 Negative
•Florida Cancer Specialists, Sarasota, Florida, United States
•Hepatocellular Carcinoma
•Emory University, Atlanta, Georgia, United States
•Urothelial Carcinoma
•Washington University School of Medicine Siteman Cancer
•Squamous Cell Carcinoma of the Head and
Center, Saint Louis, Missouri, United States
Neck
•Columbia University Medical Center, New York, New York,
•Nasopharyngeal Carcinoma
United States
•Renal Cell Carcinoma
•Duke Cancer Institute, Durham, North Carolina, United States
•Colorectal Carcinoma
•Providence Portland Medical Center, Portland, Oregon, United
•and 6 more States
•University of Pennsylvania Abramson Cancer Center,
Philadelphia, Pennsylvania, United States
•and 6 more
54 Pembrolizumab and Carboplatin in Treating Patients With Recruiting No Results Available •Estrogen Receptor Negative •Drug: Carboplatin •Northwestern University, Chicago, Illinois, United States
Circulating Tumor Cells Positive Metastatic Breast Cancer
•Estrogen Receptor Positive •Other: Laboratory Biomarker Analysis
•HER2/Neu Negative •Biological: Pembrolizumab
•Progesterone Receptor Negative
•Recurrent Breast Carcinoma
•Stage IV Breast Cancer
•Triple-Negative Breast Carcinoma
55 PALbociclib Rechallenge in horMone Receptor-posItive/ Recruiting No Results Available •Breast Cancer •Drug: Palbociclib •Hôpital Jean Minjoz, Besançon, France
HER2- Negative Advanced Breast Cancer (PALMIRA)
•Advanced Breast Cancer •Drug: Endocrine therapy •Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France
•Hormone Receptor Positive Tumor •Centre Georges François Leclerc, Dijon, France
•Human Epidermal Growth Factor 2 •CHD Vendee, La Roche-sur-Yon, France
Negative Carcinoma of Breast
•Hopital Europeen Georges Pompidou, Paris, France
•Hôpital Tenon AP-HP, Paris, France
•Centre Paul Strauss, Strasbourg, France
•University Hospital Dresden-GYN, Dresden, Germany
•Kliniken Essen Mitte, Essen, Germany
•Universitätsklinikum Essen Frauenklinik, Essen, Germany
•and 43 more

- Page 15 of 28 -
 Title Status Study Results Conditions Interventions Locations
56 ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Recruiting No Results Available •HER2-positive Breast Cancer •Drug: Vic-trastuzumab duocarmazine •University of Colorado Cancer Center, Aurora, Colorado, United
Trastuzumab Duocarmazine (SYD985) in Patients With (SYD985) + paclitaxel States
•HER2 Low
Metastatic Cancer
•SYD-985
•SYD985
•Vic-trastuzumab Duocarmazine
•Metastatic Cancer
•Metastatic Breast Cancer
•Metastatic Gastrointestinal Carcinoid
Tumor
•Metastatic
•HER2 Low Breast Cancer
•and 17 more
57 Niraparib + Dostarlimab In BRCA Mutated Breast Cancer Recruiting No Results Available •Stage I Breast Cancer •Drug: Niraparib •Johns Hopkins University, Baltimore, Maryland, United States
•Stage II Breast Cancer •Drug: Dostarlimab •Massachusetts General Hospital, Boston, Massachusetts,
United States
•Stage III Breast Cancer
•Beth Israel Deaconess Medical Center, Boston, Massachusetts,
•Breast Cancer
United States
•HER2-negative Breast Cancer
•Dana-Farber Cancer Institute, Boston, Massachusetts, United
•Germline BRCA1 Gene Mutation States
•Germline BRCA2 Gene Mutation •Mayo Clinic, Rochester, Minnesota, United States
•Deleterious PALB2 Gene Mutation •Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United
States
•Baylor College of Medicine Medical Center, Houston, Texas,
United States
•Harris Health System - Smith Clinic, Houston, Texas, United
States
58 Pembrolizumab With Carboplatin Compared to Carboplatin Recruiting No Results Available •Breast Cancer •Biological: Pembrolizumab •University of California, San Francisco, San Francisco,
Alone in Breast Cancer Patients With Chest Wall Disease California, United States
•Chest Wall Disease •Drug: Carboplatin
•Georgetown University Hospital, Washington, District of
•Biological: Trastuzumab
Columbia, United States
•University of Chicago Comprehensive Cancer Center, Chicago,
Illinois, United States
•Indiana University/Melvin and Bren Simon Cancer Center,
Indianapolis, Indiana, United States
•Massachusetts General Hospital, Boston, Massachusetts,
United States
•University of Pittsburgh Cancer Institute, Pittsburgh,
Pennsylvania, United States
•Vanderbilt University/Ingram Cancer Center, Nashville,
Tennessee, United States

- Page 16 of 28 -
 Title Status Study Results Conditions Interventions Locations
59 Study of Pembrolizumab (MK-3475) Plus Chemotherapy Recruiting No Results Available •Breast Neoplasms •Biological: pembrolizumab •Arizona Oncology Associates-Arizona Oncology ( Site 0049),
Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Tucson, Arizona, United States
•Drug: paclitaxel
Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-
•Pacific Cancer Care ( Site 0023), Monterey, California, United
B49/KEYNOTE-B49) •Drug: nab-paclitaxel
States
•Drug: liposomal doxorubicin
•UCSF Medical Center at Mission Bay ( Site 0043), San
•Drug: capecitabine Francisco, California, United States
•Drug: normal saline •Georgetown University Medical Center-Department of Medicine
and Oncology ( Site 0026), Washington, District of Columbia,
•Drug: dextrose United States
•MedStar Washington Hospital Center ( Site 0063), Washington,
District of Columbia, United States
•Baptist MD Anderson Cancer Center ( Site 0013), Jacksonville,
Florida, United States
•University Cancer & Blood Center, LLC ( Site 0032), Athens,
Georgia, United States
•Northwest Georgia Oncology Centers, a Service of Wellstar
Cobb Hospital-Research ( Site 0028), Marietta, Georgia, United
States
•University of Illinois at Chicago ( Site 0061), Chicago, Illinois,
United States
•Edward-Elmhurst Healthcare, Elmhurst Hospital-Nancy W.
Knowles Cancer Center ( Site 0067), Elmhurst, Illinois, United
States
•and 183 more
60 The PROMISE Study: Duavee in Women With DCIS Recruiting No Results Available •Ductal Breast Carcinoma In Situ •Drug: Conjugated Estrogens/Bazedoxifene •University of Colorado at Denver/ Department of Surgery,
Aurora, Colorado, United States
•Postmenopausal •Other: Laboratory Biomarker Analysis
•Northwestern University, Chicago, Illinois, United States
•Other: Pharmacological Study
•Northwestern Medicine - Delnor/Warrenville Cancer Centers/
•Other: Placebo
Central DuPage Hospital, Geneva, Illinois, United States
•Procedure: Quality-of-Life Assessment
•Northwestern University, Lake Forest, Illinois, United States
•Other: Questionnaire Administration
•John's Hopkins University, Baltimore, Maryland, United States
•Dana Farber/Partners Cancer Care Inc, Boston, Massachusetts,
United States
•Washington University in St. Louis/ Siteman Cancer Center,
Saint Louis, Missouri, United States
•Thomas Jefferson University, Philadelphia, Pennsylvania,
United States
•University of Pittsburg/ Magee-Womens Hospital, Pittsburgh,
Pennsylvania, United States
•Huntsman Cancer Institute, Salt Lake City, Utah, United States
61 Roll-over Study to Allow Continued Access to Ribociclib Recruiting No Results Available •Metastatic Breast Cancer •Drug: Ribociclib •Mid Florida Hematology and Oncology Center, Orange City,
Florida, United States
•Drug: Letrozole
•Summit Cancer Care, Savannah, Georgia, United States
•Drug: Anastrozole
•John D Archbold Memorial Hospital, Thomasville, Georgia,
•Drug: Goserelin
United States
•Drug: Tamoxifen
•Millennium Research Clin Develop, Houston, Texas, United
•Drug: Fulvestrant States
•Novartis Investigative Site, Gdansk, Poland
•Novartis Investigative Site, Singapore, Singapore

- Page 17 of 28 -
 Title Status Study Results Conditions Interventions Locations
62 Study of Intravaginal Tamoxifen in PostMenopausal Women Recruiting No Results Available •Vulvar Atrophy •Drug: Tamoxifen •PARC Clinical Research, Adelaide, Southern Australia, Australia
With VVA
•Other: Placebo •Keogh Institute for Medical Research, Nedlands, Western
Australia, Australia
63 Ovarian Suppression Evaluating Subcutaneous Leuprolide Recruiting No Results Available •Breast Cancer •Drug: TOL2506 •Marin Cancer Care, Inc, Greenbrae, California, United States
Acetate in Breast Cancer
•Drug: Tamoxifen •Holy Cross Hospital - Bienes Cancer Center, Fort Lauderdale,
Florida, United States
•Drug: Letrozole Tablets
•BRCR Medical Cancer Center Inc., Plantation, Florida, United
•Drug: Anastrozole Tablets
States
•Drug: Exemestane Tablets
•Northwestern Medicine Cancer Center, Warrenville, Illinois,
United States
•Cancer Center of Kansas, Wichita, Kansas, United States
•Baptist Health Lexington, Lexington, Kentucky, United States
•Baptist Health Louisville, Louisville, Kentucky, United States
•Hematology Oncology Clinic, Baton Rouge, Louisiana, United
States
•University of Maryland, St. Joseph Medical Center, Cancer
Institute, Towson, Maryland, United States
•Revive Research Institute, Inc., Farmington Hills, Michigan,
United States
•and 14 more
64 A Study of TY-302 in Patients With Advanced Solid Tumors Recruiting No Results Available •Breast Cancer •Drug: TY-302: capsule, 25mg/50mg ; •Chinese Academy of Medical Sciences and Peking Union
Tamoxifen: tablet,10mg Medical Colledge, Beijing, Beijing, China
•Solid Tumor
65 Study of AZD9833 Alone or in Combination in Women With Recruiting No Results Available •ER+ HER2- Advanced Breast Cancer •Drug: AZD9833 •Research Site, Aurora, Colorado, United States
Advanced Breast Cancer.
•Drug: AZD9833 with palbociclib •Research Site, Sarasota, Florida, United States
•Drug: AZD9833 with everolimus •Research Site, Philadelphia, Pennsylvania, United States
•Drug: AZD9833 with abemaciclib •Research Site, Nashville, Tennessee, United States
•Drug: AZD9833 with capivasertib •Research Site, Salt Lake City, Utah, United States
•Research Site, Barcelona, Spain
•Research Site, Barcelona, Spain
•Research Site, Madrid, Spain
•Research Site, Madrid, Spain
•Research Site, Sevilla, Spain
•and 7 more
66 A Randomized, Open-label, Multi-center Phase IV Study Recruiting No Results Available •Metastatic Breast Cancer •Drug: Palbociclib / Chemotherapy •Agaplesion Markus Krankenhaus - Klinik für Gynäkologie und
Evaluating Palbociclib Plus Endocrine Treatment Versus a (capecitabine, epirubicin, paclitaxel, Geburtshilfe, Frankfurt am Main, Germany
Chemotherapy-based Treatment Strategy in Patients With vinorelbine) / Endocrine therapy
Hormone Receptor Positive / HER2 Negative Breast Cancer in (exemestane, fulvestrant, letrozole,
a Real World Setting (GBG 93 - PADMA Study). tamoxifen)
67 A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Recruiting No Results Available •Breast Cancer •Drug: Zanidatamab •M D Anderson Cancer Center, Houston, Texas, United States
Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu
•HER2-positive •Drug: Letrozole
Positive (HER2+) Breast Cancer (BC)
•Drug: Tamoxifen

- Page 18 of 28 -
 Title Status Study Results Conditions Interventions Locations
68 A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Recruiting No Results Available •HER2-positive Breast Cancer •Combination Product: Pertuzumab •Stamford Hospital, Stamford, Connecticut, United States
Pertuzumab, and Trastuzumab for Patients With Anatomic +TRASTUZUMAB
•Invasive Carcinoma of the Breast •Winship Cancer Institute at Emory University Hospital Midtown,
Stage I Hormone Receptor-positive, HER2-positive Breast
•Drug: ADJUVANT ENDOCRINE THERAPY Atlanta, Georgia, United States
Cancer •Breast Cancer
•Emory University - Winship Cancer Institute, Atlanta, Georgia,
•Node Negative Breast Cancer
United States
•Micrometastasis Breast Cancer
•Winship Cancer Institute at Emory Saint Joseph's Hospital,
•Hormone Receptor Positive Breast Cancer Atlanta, Georgia, United States
•Indiana University Health Schwarz Cancer Center, Indianapolis,
Indiana, United States
•Indiana University Health - Melvin and Bren Simon Cancer
Center, Indianapolis, Indiana, United States
•Indiana University Sidney and Lois Eskenazi Hospital,
Indianapolis, Indiana, United States
•Eastern Maine Medical Center (Northern Light), Brewer, Maine,
United States
•Dana Farber Cancer Institite, Boston, Massachusetts, United
States
•Beth Israel Deaconess Medical Center, Boston, Massachusetts,
United States
•and 5 more
69 Study of MT-5111 in HER2-positive Solid Tumors Recruiting No Results Available •HER2-positive Solid Cancers •Drug: MT-5111 (experimental study drug) •Mayo Clinic (Arizona), Phoenix, Arizona, United States
•St. Joseph Heritage Healthcare, Fullerton, California, United
States
•Cancer and Blood Specialty Clinic, Los Alamitos, California,
United States
•Cedars-Sinai Medical Center, Santa Monica, California, United
States
•UCLA Hematology & Oncology, Santa Monica, California,
United States
•Sarah Cannon Research Institute, Denver, Colorado, United
States
•Sylvester Comprehensive Cancer Center (University of Miami),
Coral Gables, Florida, United States
•South Broward Hospital District d/b/a Memorial Healthcare
System, Hollywood, Florida, United States
•Mayo Clinic (Florida), Jacksonville, Florida, United States
•Orlando Health, Orlando, Florida, United States
•and 20 more
70 A Study of LOXO-783 in Patients With Breast Cancer/Other Recruiting No Results Available •Breast Cancer •Drug: LOXO-783 •Massachusetts General Hospital, Boston, Massachusetts,
Solid Tumors United States
•Drug: Fulvestrant
•Memorial Sloan Kettering Cancer Center, New York, New York,
•Drug: Imlunestrant
United States
•Drug: Abemaciclib
•Tennessee Oncology PLLC, Nashville, Tennessee, United
•Drug: Anastrozole, Exemestane, or States
Letrozole
•University of Texas MD Anderson Cancer Center, Houston,
•Drug: Paclitaxel Texas, United States
•South Texas Accelerated Research Therapeutics, LLC, San
Antonio, Texas, United States

- Page 19 of 28 -
 Title Status Study Results Conditions Interventions Locations
71 A Phase 1b Study of T-DXd Combinations in HER2-low Recruiting No Results Available •Metastatic Breast Cancer •Drug: Trastuzumab deruxtecan •Research Site, Iowa City, Iowa, United States
Advanced or Metastatic Breast Cancer
•Drug: Durvalumab •Research Site, Minneapolis, Minnesota, United States
•Drug: Paclitaxel •Research Site, Saint Paul, Minnesota, United States
•Drug: Capivasertib •Research Site, Basking Ridge, New Jersey, United States
•Drug: Anastrozole •Research Site, Middletown, New Jersey, United States
•Drug: Fulvestrant •Research Site, Montvale, New Jersey, United States
•Drug: Capecitabine •Research Site, Ridgewood, New Jersey, United States
•Research Site, Commack, New York, United States
•Research Site, Harrison, New York, United States
•Research Site, Long Island City, New York, United States
•and 50 more
72 A Phase Ib Study of HS-10352 Plus Fulvestrant in Patients Recruiting No Results Available •Breast Cancer •Drug: HS-10352 combined with fulvestrant •Fudan University Shanghai Cancer Center, Shanghai,
With Advanced Breast Cancer (Stage 1) Shanghai, China
•Drug: HS-10352 combined with fulvestrant
(Stage 2)
73 (VELA) Study of BLU-222 in Advanced Solid Tumors Recruiting No Results Available •ER+ Breast Cancer •Drug: BLU-222 •Florida Cancer Specialists, Sarasota, Florida, United States
•CCNE1 Amplification •Drug: Carboplatin •Massachusetts General Hospital, Boston, Massachusetts,
United States
•HER2-negative Breast Cancer •Drug: Ribociclib
•Columbia University Herbert Irving Comprehensive Cancer
•Advanced Solid Tumor •Drug: Fulvestrant
Center, New York, New York, United States
•Ovarian Cancer
•MD Anderson Cancer Center, Houston, Texas, United States
•Endometrial Cancer
•Gastric Cancer
•Esophageal Adenocarcinoma
•Carcinosarcoma
74 CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Recruiting No Results Available •Advanced Solid Tumor •Drug: CFI-402257 •The Ohio State University Comprehensive Cancer Center,
Tumors and With Fulvestrant in Breast Cancer Columbus, Ohio, United States
•Breast Cancer •Drug: Fulvestrant
•START San Antonio, San Antonio, Texas, United States
•START - Mountain Region, West Valley City, Utah, United
States
75 First-in-Human Study of Mutant-selective PI3K# Inhibitor, Recruiting No Results Available •PIK3CA Mutation •Drug: RLY-2608 •HealthONE, Denver, Colorado, United States
RLY-2608, as a Single Agent in Advanced Solid Tumor
•Solid Tumor, Adult •Drug: Fulvestrant •Florida Cancer Specialists, Orlando, Florida, United States
Patients and in Combination With Fulvestrant in Patients With
Advanced Breast Cancer •HER2-negative Breast Cancer •Massachusetts General Hospital, Boston, Massachusetts,
United States
•Breast Cancer
•Columbia University Herbert Irving Comprehensive Cancer
•Metastatic Breast Cancer
Center, New York, New York, United States
•Advanced Breast Cancer
•Memorial Sloan Kettering, New York, New York, United States
•Unresectable Solid Tumor
•Tennessee Oncology, Nashville, Tennessee, United States
•The University of Texas M.D. Anderson Cancer Center,
Houston, Texas, United States
•NEXT Virginia, Fairfax, Virginia, United States

- Page 20 of 28 -
 Title Status Study Results Conditions Interventions Locations
76 Abemaciclib (LY2835219) Plus Fulvestrant Compared to Recruiting No Results Available •Breast Neoplasm •Drug: Abemaciclib •St. Joseph's Hospital and Medical Center, Phoenix, Arizona,
Placebo Plus Fulvestrant in Previously Treated Breast Cancer United States
•Neoplasm Metastasis •Drug: Fulvestrant
•Highlands Oncology Group, Springdale, Arkansas, United
•Drug: Placebo
States
•Providence Medical Foundation, Fullerton, California, United
States
•Cancer and Blood Specialty Clinic, Los Alamitos, California,
United States
•TRIO-US (Translational Research in Oncology-US), Los
Angeles, California, United States
•Keck School of Medicine of USC, Los Angeles, California,
United States
•UCLA Hematology/Oncology - Parkside, Santa Monica,
California, United States
•Olive View-UCLA Medical Center, Sylmar, California, United
States
•Torrance Memorial Physician Network / Cancer Care, Torrance,
California, United States
•PIH Health Hematology Medical Oncology, Whittier, California,
United States
•and 133 more
77 A Study of XZP-3287 in Combination With Fulvestrant in Recruiting No Results Available •Advanced Breast Cancer •Drug: XZP-3287+Fulvestrant •Chinese Academy of Medical Science, Beijing, Beijing, China
Patients With Advanced Breast Cancer
•Drug: Placebo + Fulvestrant
78 GB491 Combined With Fulvestrant for HR+ HER2- Locally Recruiting No Results Available •Locally Advanced or Metastatic Breast •Drug: GB491+ Fulvestrant •The First Affiliated Hospital of Bengbu Medical College, Bengbu,
Advanced or Metastatic Breast Cancer Cancer Anhui, China
•Drug: Placebo+Fulvestrant
•Anhui Provincial Cancer Hospital, Hefei, Anhui, China
•The Second Hospital of Anhui Medical University, Hefei, Anhui,
China
•Beijing Chaoyang Hospital of Capital Medical University, Beijing,
Beijing, China
•Cancer hospital Chinese Academy of Medical Sciences, Beijing,
Beijing, China
•Chinese PLA General Hospital, Beijing, Beijing, China
•Beijing Tiantan Hospital , Capital Medical University, Beijing,
Beijing, China
•Chongqing University Cancer Hospital, Chongqing, Chongqing,
China
•The First Affiliated Hospital of Chongqing Medical University,
Chongqing, Chongqing, China
•Chognqing University Three Gorges Hospital, Chongqing,
Chongqing, China
•and 44 more

- Page 21 of 28 -
 Title
79 Study to Assess the Efficacy and Safety of Alpelisib Plus Recruiting
Fulvestrant in Participants With HR-postitive (HR+), HER2-
negative, Advanced Breast Cancer After Treatment With a
CDK4/6 Inhibitor and an Aromatase Inhibitor.
80 Capivasertib + Palbociclib + Fulvestrant for HR+/HER2- Recruiting
Advanced Breast Cancer (CAPItello-292).
81 Pilot Decentralized Clinical Trial in Men and Pre and Post- Recruiting
menopausal Women With Breast Cancer and a Specific
Mutation (PIK3CA) Treated With Alpelisib in Combination With
Fulvestrant
82 Study Evaluating Efficacy & Safety of Afuresertib Plus Recruiting
Fulvestrant in Patients w/ Locally Advanced or Metastatic HR
+/HER2- Breast Cancer
Status Study Results Conditions
No Results Available •Breast Cancer
No Results Available •Locally Advanced (Inoperable) or
Metastatic Breast Cancer
No Results Available •Advanced Breast Cancer
No Results Available •Breast Cancer
- Page 22 of 28 -
Interventions Locations
•Drug: Alpelisib •Novartis Investigative Site, Sint Niklaas, Vlaams Brabant,
Belgium
•Drug: Fulvestrant
•Novartis Investigative Site, Bruxelles, Belgium
•Drug: Alpelisib-matching placebo
•Novartis Investigative Site, Leuven, Belgium
•Novartis Investigative Site, Liege, Belgium
•Novartis Investigative Site, Burgas, Bulgaria
•Novartis Investigative Site, Plovdiv, Bulgaria
•Novartis Investigative Site, Sofia, Bulgaria
•Novartis Investigative Site, Ottawa, Ontario, Canada
•Novartis Investigative Site, Novy Jicin, Czech Republic, Czechia
•Novartis Investigative Site, Brno, Czechia
•and 60 more
•Drug: Capivasertib •Research Site, Los Angeles, California, United States
•Drug: Matched Capivasertib Placebo •Research Site, San Francisco, California, United States
•Drug: Fulvestrant •Research Site, Aurora, Colorado, United States
•Drug: Palbociclib •Research Site, Nashville, Tennessee, United States
•Research Site, San Antonio, Texas, United States
•Research Site, Darlinghurst, Australia
•Research Site, Miranda, Australia
•Research Site, Nedlands, Australia
•Research Site, Perth, Australia
•Research Site, Wahroonga, Australia
•and 55 more
•Drug: Alpelisib •Novartis Investigative Site, Orebro, Sweden
•Drug: fulvestrant
•Drug: Afuresertib •Providence St. Johns Health Center, Santa Monica, California,
United States
•Piedmont Cancer Institute, Atlanta, Georgia, United States
•University of Iowa, Iowa City, Iowa, United States
•University of Mississippi Medical Center, Jackson, Mississippi,
United States
•University of Vermont, Burlington, Vermont, United States
•Virginia Cancer Specialists, Fairfax, Virginia, United States
•Cancer Hospital Chinese Academy of Medical Sciences, Beijing,
Beijing, China
•Sun Yat-sen Memorial Hospital of Sun Yat-sen University,
Guangzhou, Guangdong, China
•The 1st Bethune Hospital of Jilin University, Changchun, Jilin,
China
•Liaoning Province Cancer Hospital, Shenyang, Liaoning, China
•Sir-run run shaw Hospital Zhejiang University of Medicine,
Hangzhou, Zhejiang, China
•Tianjin Medical University Cancer Institute & Hospital, Tianjin,
China
 Title Status Study Results Conditions Interventions Locations
83 A Study of TQB3616 Capsules Combined With Fulvestrant Recruiting No Results Available •HR-positive, HER2-negative Advanced •Drug: TQB3616 capsules •The Fifth Medical Center of PLA General Hospital, Beijing,
Injection in Subjects With Advanced Breast Cancer Breast Cancer Beijing, China
•Drug: Fulvestrant injection
•Chongqing University Cancer Hospital, Chongqing, Chongqing,
China
•Gansu Provincial Hostipal, Lanzhou, Gansu, China
•Guangdong General Hospital, Guangzhou, Guangdong, China
•Sun Yat-sen University Cancer Center, Guangzhou,
Guangdong, China
•Guangxi Medical University Affiliated Tumor Hospital, Nanning,
Guangxi, China
•The Fourth Hospital of Hebei Medical University, Shijiazhuang,
Hebei, China
•Harbin Medical University Affiliated Cancer Hospital, Harbin,
Heilongjiang, China
•Hunan Cancer Hospital, Changsha, Hunan, China
•Jiangsu Province Hospital, Nanjing, Jiangsu, China
•and 7 more
84 A Study of Abemaciclib in Indian Women With Advanced Recruiting No Results Available •Breast Neoplasms •Drug: Abemaciclib •MNJ Institute of Oncology, Hyderabad, Andhra Pradesh, India
Breast Cancer
•Neoplasm Metastasis •Drug: Nonsteroidal Aromatase Inhibitor •Indira Gandhi Institute of Medical Sciences, Patna, Bihar, India
(NSAI)
•Rajiv Gandhi Cancer Institute And Research Centre, New Delhi,
•Drug: Fulvestrant Delhi, India
•Nirmal Hospital Pvt Ltd., Surat, Gujarat, India
•Unique Hospital Multispecialty & Research Institute, Surat,
Gujarat, India
•Anand Multispeciality Hospital, Vadodara, Gujarat, India
•Kailash Cancer Hospital & Research Centre (KCHRC),
Waghodia, Gujarat, India
•HCG Cancer Centre, Kalinga Rao Road, Bengaluru, Karnataka,
India
•Regional Cancer Centre, Trivandrum, Kerala, India
•SRJ-CBCC Cancer Hospital, Indore, Madhya Pradesh, India
•and 6 more
85 Study Assessing the Efficacy and Safety of Treatment With Recruiting No Results Available •Breast Neoplasms •Drug: Alpelisib •Novartis Investigative Site, Hefei, Anhui, China
Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in
•Drug: Fulvestrant •Novartis Investigative Site, Chongqing, Chongqing, China
Chinese Men and Postmenopausal Women With Advanced
Breast Cancer •Drug: Placebo •Novartis Investigative Site, Guangzhou, Guangdong, China
•Novartis Investigative Site, Guangzhou, Guangdong, China
•Novartis Investigative Site, Shijiazhuang, Hebei, China
•Novartis Investigative Site, Harbin, Heilongjiang, China
•Novartis Investigative Site, Wuhan, Hubei, China
•Novartis Investigative Site, Changsha, Hunan, China
•Novartis Investigative Site, Nanjing, Jiangsu, China
•Novartis Investigative Site, Nanjing, Jiangsu, China
•and 17 more

- Page 23 of 28 -
 Title
86 Study Assessing the Efficacy and Safety of Treatment
With Alpelisib Plus Fulvestrant in Japanese Men and
Postmenopausal Women With Advanced Breast Cancer
87 Capivasertib+Fulvestrant vs Placebo+Fulvestrant as
Treatment for Locally Advanced (Inoperable) or Metastatic HR
+/HER2- Breast Cancer
88 A Study of ZW25 (Zanidatamab) With Palbociclib Plus
Fulvestrant in Patients With HER2+/HR+ Advanced Breast
Cancer
Status Study Results Conditions Interventions Locations
Recruiting No Results Available •Advanced Breast Cancer •Drug: Alpelisib •Novartis Investigative Site, Nagoya-city, Aichi, Japan
•Drug: Fulvestrant •Novartis Investigative Site, Nagoya, Aichi, Japan
•Novartis Investigative Site, Kashiwa, Chiba, Japan
•Novartis Investigative Site, Isehara, Kanagawa, Japan
•Novartis Investigative Site, Yokohama-city, Kanagawa, Japan
•Novartis Investigative Site, Kumamoto City, Kumamoto, Japan
•Novartis Investigative Site, Osaka-city, Osaka, Japan
•Novartis Investigative Site, Osaka-city, Osaka, Japan
•Novartis Investigative Site, Bunkyo ku, Tokyo, Japan
•Novartis Investigative Site, Koto ku, Tokyo, Japan
Recruiting No Results Available •Locally Advanced (Inoperable) or •Drug: Fulvestrant •Research Site, Gilbert, Arizona, United States
Metastatic Breast Cancer
•Drug: Capivasertib •Research Site, Tucson, Arizona, United States
•Drug: Placebo •Research Site, Tucson, Arizona, United States
•Research Site, Orange, California, United States
•Research Site, Redlands, California, United States
•Research Site, San Francisco, California, United States
•Research Site, Santa Maria, California, United States
•Research Site, Thousand Oaks, California, United States
•Research Site, Whittier, California, United States
•Research Site, Whittier, California, United States
•and 256 more
Recruiting No Results Available •HER2+/HR+ Breast Cancer •Drug: ZW25 (Zanidatamab) •UCLA Hematology/Oncology Parkside, Santa Monica,
California, United States
•Drug: Palbociclib
•Sarah Cannon Research Institute, Nashville, Tennessee, United
•Drug: Fulvestrant
States
•South Texas Accelerated Research Therapeutics, San Antonio,
Texas, United States
•Seattle Cancer Care Alliance, Seattle, Washington, United
States
•Tom Baker Cancer Centre, Calgary, Alberta, Canada
•The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada
•Sunnybrook Research Institute, Toronto, Ontario, Canada
•Jewish General Hospital, Montreal, Quebec, Canada
•Hospital General Universitario de Elche, Elche, Alicante, Spain
•Hospital Universitario Vall d'Hebrón, Barcelona, Spain
•and 4 more
- Page 24 of 28 -
 Title Status Study Results Conditions Interventions Locations
89 A Study Evaluating the Efficacy and Safety of Inavolisib Recruiting No Results Available •Breast Cancer •Drug: Inavolisib •Arizona Oncology Associates, PC-CASA, Tucson, Arizona,
+ Palbociclib + Fulvestrant vs Placebo + Palbociclib + United States
•Drug: Placebo
Fulvestrant in Patients With PIK3CA-Mutant, Hormone
•Beverly Hills Cancer Center, Beverly Hills, California, United
Receptor-Positive, Her2-Negative, Locally Advanced or •Drug: Palbociclib
States
Metastatic Breast Cancer
•Drug: Fulvestrant
•Kaiser Permanente;Clinical Trials Department, Denver,
Colorado, United States
•Norwalk Hospital, Norwalk, Connecticut, United States
•Florida Cancer Specialists - Fort Myers (Broadway), Fort Myers,
Florida, United States
•Memorial Healthcare System - Memorial Regional Hospital,
Hollywood, Florida, United States
•Florida Cancer Specialists (St. Petersburg - St. Anthony's
Professional Building), Saint Petersburg, Florida, United States
•SCRI Florida Cancer Specialists PAN, Tallahassee, Florida,
United States
•SCRI Florida Cancer Specialists East, West Palm Beach,
Florida, United States
•Winship Cancer Institute of Emory University, Atlanta, Georgia,
United States
•and 219 more
90 A Study of TAS-120 in Patients With Metastatic Breast Cancer Recruiting No Results Available •Metastatic Breast Cancer •Drug: Futibatinib •Mayo Clinic - AZ, Phoenix, Arizona, United States
•FGFR 1 High Amplification •Drug: Futibatinib plus Fulvestrant •USCF, San Francisco, California, United States
•FGFR2 Amplification •Florida Cancer Specialists, Fort Myers, Florida, United States
•Mayo Clinic - FL, Jacksonville, Florida, United States
•Florida Cancer Specialists, Saint Petersburg, Florida, United
States
•Florida Cancer Specialists, Tallahassee, Florida, United States
•Florida Cancer Specialists, West Palm Beach, Florida, United
States
•Massachusetts General Hospital, Boston, Massachusetts,
United States
•Dana Farber Cancer Institute, Boston, Massachusetts, United
States
•Mayo Clinic - MN, Rochester, Minnesota, United States
•and 27 more

- Page 25 of 28 -
 Title Status Study Results Conditions Interventions Locations
91 Basket Study of Tucatinib and Trastuzumab in Solid Tumors Recruiting No Results Available •Uterine Neoplasms •Drug: tucatinib •Arizona Oncology Associates, PC - HAL, Goodyear, Arizona,
With HER2 Alterations United States
•Uterine Cervical Neoplasms •Drug: trastuzumab
•HonorHealth, Phoenix, Arizona, United States
•Biliary Tract Neoplasms •Drug: fulvestrant
•Mayo Clinic Arizona, Phoenix, Arizona, United States
•Urologic Neoplasms
•Arizona Cancer Center / University of Arizona, Tucson, Arizona,
•Carcinoma, Non-Small-Cell Lung
United States
•HER2 Mutations Breast Neoplasms
•UC San Diego / Moores Cancer Center, La Jolla, California,
United States
•Pacific Shores Medical Group, Long Beach, California, United
States
•Rocky Mountain Cancer Centers, Boulder, Colorado, United
States
•Regional Cancer Care Associates, Manchester, Connecticut,
United States
•Lombardi Cancer Center / Georgetown University Medical
Center, Washington, District of Columbia, United States
•Mayo Clinic Florida, Jacksonville, Florida, United States
•and 54 more
92 Study of eFT226 in Subjects With Selected Advanced Solid Recruiting No Results Available •Solid Tumor, Adult •Drug: eFT226 •University of Southern California, Los Angeles, California,
Tumor Malignancies United States
•Drug: Sotorasib
•Stanford University, Palo Alto, California, United States
•Drug: Fulvestrant
•Hoag Memorial Hospital Presbyterian, Tustin, California, United
•Drug: Abemaciclib
States
•Drug: Trastuzumab
•START Midwest, Grand Rapids, Michigan, United States
•Memorial Sloan Kettering Cancer Center, Middletown, New
Jersey, United States
•Memorial Sloan Kettering Cancer Center, Harrison, New York,
United States
•Memorial Sloan Kettering Cancer Center, New York, New York,
United States
•University of Toledo, Toledo, Ohio, United States
•MD Anderson Cancer Center, Houston, Texas, United States
•Virginia Cancer Specialists, Fairfax, Virginia, United States
93 A Study of Lerociclib in Participants With Advanced Breast Recruiting No Results Available •Advanced Breast Cancer •Drug: Lerociclib + Letrozole or Fulvestrant •Cancer Specialists of North Florida, Jacksonville, Florida, United
Cancer States
•Nebraska Cancer Specialists, Omaha, Nebraska, United States
•Oregon Oncology Specialists, Salem, Oregon, United States
•Cancer Care Associates of York, Inc., York, Pennsylvania,
United States
•Northwest Medical Specialties PLLC, Tacoma, Washington,
United States
•IMSP Institutul Oncologic, Arsenia Exploratory Medicine,
Chisinau, Moldova, Republic of

- Page 26 of 28 -
 Title Status Study Results Conditions Interventions Locations
94 Study of Safety and Efficacy of Dapagliflozin + Metformin Recruiting No Results Available •Breast Cancer •Drug: Alpelisib •Alaska Oncology and Hematology AOH (2), Anchorage, Alaska,
XR Versus Metformin XR in Participants With HR+, HER2-, United States
•Drug: Fulvestrant
Advanced Breast Cancer While on Treatment With Alpelisib
•Kaiser Permanente Medical Group Kaiser Hawaii -, Anaheim,
and Fulvestrant •Drug: Metformin XR
California, United States
•Drug: Dapagliflozin + metformin XR
•Rocky Mountain Cancer Centers RMCC Hale Pkwy, Longmont,
•Drug: Dapagliflozin Colorado, United States
•Georgia Cancer Specialists, Decatur, Georgia, United States
•Washington University School of Medicine Siteman Cancer
Center, Saint Louis, Missouri, United States
•St Vincent Frontier Cancer Center, Billings, Montana, United
States
•Astera Cancer Center, East Brunswick, New Jersey, United
States
•Texas Oncology Austin, Austin, Texas, United States
•Texas Oncology PA Dallas Presbyterian Hospital SC, Dallas,
Texas, United States
•Tx Onco Sammons Cancer Center, Dallas, Texas, United States
•and 12 more
95 Study of XL102 as Single-Agent and Combination Therapy in Recruiting No Results Available •Neoplasm Malignant •Drug: XL102 •Exelixis Clinical Site #4, Atlanta, Georgia, United States
Subjects With Solid Tumors (QUARTZ-101)
•Epithelial Ovarian Cancer •Drug: Fulvestrant •Exelixis Clinical Site #3, Boston, Massachusetts, United States
•Triple Negative Breast Cancer •Drug: Abiraterone •Exelixis Clinical Site #2, Dallas, Texas, United States
•Hormone Receptor Positive Breast •Drug: Prednisone •Exelixis Clinical Site #5, Houston, Texas, United States
Carcinoma
•Exelixis Clinical Site #1, San Antonio, Texas, United States
•Metastatic Castration-resistant Prostate
Cancer
96 Study of PF-07248144 in Advanced or Metastatic Solid Recruiting No Results Available •Locally Advanced or Metastatic ER+ HER2- •Drug: PF-07248144 •HonorHealth, Scottsdale, Arizona, United States
Tumors Breast Cancer
•Drug: Fulvestrant •Cedars Sinai Medical Center, Samuel Oschin Comprehensive
•Locally Advanced or Metastatic Castration- Cancer Institute, Los Angeles, California, United States
•Drug: Letrozole
resistant Prostate Cancer
•Cedars-Sinai Medical Center; SOCCI Pharmacy, Los Angeles,
•Drug: Palbociclib
•Locally Advanced or Metastatic Non-small California, United States
Cell Lung Cancer
•UCSF Medical Center at Mission Bay, San Francisco, California,
United States
•Smilow Cancer Hospital at Yale - New Haven, New Haven,
Connecticut, United States
•Smilow Cancer Hospital Phase 1 Unit, New Haven, Connecticut,
United States
•Yale New Haven Hospital, New Haven, Connecticut, United
States
•Holy Cross Hospital, Fort Lauderdale, Florida, United States
•James Graham Brown Cancer Center, Louisville, Kentucky,
United States
•University Medical Center, lnc.:DBA University of Louisville
Hospital, Louisville, Kentucky, United States
•and 33 more

- Page 27 of 28 -
 Title Status Study Results Conditions Interventions Locations
97 Study to Test the Safety and Tolerability of PF-07220060 in Recruiting No Results Available •Liposarcoma •Drug: PF-07220060 •Smilow Cancer Hospital at Yale - New Haven, New Haven,
Participants With Advance Solid Tumors Connecticut, United States
•CRC •Combination Product: Letrozole
•Smilow Cancer Hospital Phase 1 Unit, New Haven, Connecticut,
•Prostate Cancer •Combination Product: Fulvestrant
United States
•Breast Neoplasms
•Brigham & Women's Hospital, Boston, Massachusetts, United
•Adenocarcinoma of Lung States
•Solid Tumors •Dana-Farber Cancer Institute (DFCI), Boston, Massachusetts,
United States
•Dana-Farber Cancer Institute, Boston, Massachusetts, United
States
•START Midwest, Grand Rapids, Michigan, United States
•Sarah Cannon Research Institute, Nashville, Tennessee, United
States
•Tennessee Oncology, PLLC, Nashville, Tennessee, United
States
•The University of Texas MD Anderson Cancer Center, Houston,
Texas, United States
98 PF-07104091 as a Single Agent and in Combination Therapy Recruiting No Results Available •Small Cell Lung Cancer •Drug: PF-07104091 monotherapy dose •Medical Oncology & Hematology Associates DBA Mission
escalation Cancer and Blood, Clive, Iowa, United States
•Ovarian Cancer
•Drug: PF-07104091 + palbociclib + •Des Moines Oncology Research Association, Des Moines, Iowa,
•Breast Cancer
fulvestrant United States
•Triple-Negative Breast Cancer
•Drug: PF-07104091 + palbociclib + •Medical Oncology & Hematology Associates DBA Mission
•Non Small Cell Lung Cancer letrozole Cancer and Blood, Des Moines, Iowa, United States
•Drug: PF-07104091 monotherapy dose •Medical Oncology & Hematology Associates DBA Mission
expansion (ovarian) Cancer and Blood, Des Moines, Iowa, United States
•Drug: PF-07104091 monotherapy dose •Norton Cancer Institute Downtown, Louisville, Kentucky, United
expansion (SCLC) States
•Drug: PF-07104091 monotherapy dose •Norton Cancer Institute Pharmacy, Downtown Pharmacy,
expansion (TNBC) Louisville, Kentucky, United States
•Drug: PF-07104091 + palbociclib + •Norton Cancer Institute, Downtown, Louisville, Kentucky, United
fulvestrant (post CDK4/6) States
•Drug: PF-07104091 + palbociclib + •Norton Hospital, Louisville, Kentucky, United States
fulvestrant (CDK4/6 naive)
•Norton Diagnostic Center - Dupont, Louisville, Kentucky, United
•Drug: PF-07104091 + palbociclib + States
letrozole (CDK4/6 naive)
•Brownsboro Diagnostic Center, Louisville, Kentucky, United
States
•and 13 more
99 A Study of BPI-1178 in Patients With Advanced Solid Tumor Recruiting No Results Available •Advanced Solid Tumor •Drug: BPI-1178 •Fudan University Shanghai Cancer Center, Shanghai,
and HR+/HER2- Breast Cancer Shanghai, China
•Breast Neoplasms •Drug: Fulvestrant
•Drug: Letrozole
100 Study Evaluating Hemay022 in Combination With Endocrine Recruiting No Results Available •Breast Cancer •Drug: Hemay022+exemestane •Beijing Cancer Hospital, Beijing, China
Therapy In Subjects With ER Positive and HER2 Positive
•Drug: Hemay022+letrozole
Advanced Breast Cancer
•Drug: Hemay022+ fulvestrant

23 additional studies not shown

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services

- Page 28 of 28 -